Kikly, IN
Kristine K. Kikly, Fortville, IN US
Patent application number | Description | Published |
---|---|---|
20080213212 | Sialoadhesin factor-2 antibodies - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents | 09-04-2008 |
20100056760 | SIALOADHESIN FACTOR-2 ANTIBODIES - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents. | 03-04-2010 |
20110217319 | METHODS OF USE OF SIALOADHESIN FACTOR-2 ANTIBODIES - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents | 09-08-2011 |
Kristine Kay Kikly, Fortville, IN US
Patent application number | Description | Published |
---|---|---|
20090060920 | DESACYL GHRELIN ANTIBODIES AND THERAPEUTIC USES THEREOF - A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention. | 03-05-2009 |
20090240036 | Anti-IL-23 Antibodies - The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease. | 09-24-2009 |
20100272735 | METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES - Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K | 10-28-2010 |
20120195904 | METHOD TO TREAT USING ANTAGONISTIC ANTI-hTNFSF13B HUMAN ANTIBODIES - Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K | 08-02-2012 |
Kristine Kay Kikly, Spiceland, IN US
Patent application number | Description | Published |
---|---|---|
20140255422 | ANTIBODIES THAT BIND TO IL-23 - The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer. | 09-11-2014 |
20140271647 | Pan-ELR+ CXC CHEMOKINE ANTIBODIES - Antibodies are provided that specifically bind seven human ELR | 09-18-2014 |